Robert Recaps a Career of Clinical Research in Melanoma
December 7th 2020In our exclusive interview, Caroline Robert, MD, PhD, discusses her groundbreaking work on clinical trials evaluating anti–CTLA-4 and anti–PD-1 antibodies in advanced melanoma, her experiences as a researcher in France and the United States, her love of traveling, and next steps for the field.
Read More
Huntsman Homes in on the Integration of Precision Medicine in Oncology
December 3rd 2020In our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.
Read More
Marvels in Medicine: Dr. Karlan on Creating Continuous Quality Improvement in Gynecologic Oncology
November 30th 2020In our exclusive interview, Dr. Karlan discusses pivotal moments in her career as a gynecologic oncologist, the challenges of forging a name for herself, and future directions for the field.
Read More
Loaiza-Bonilla on Applications, Actionability, and Affordability of AI in Oncology
November 26th 2020In our exclusive interview, Dr. Loaiza-Bonilla explains how AI can be used to optimize patient care, provides insight into the research that has been done to develop potential applications for AI in oncology, and sheds light on some of the barriers that have to be overcome in order to effectively implement AI in oncology.
Read More
Oxnard on Opening the Door for Precision Medicine in Lung Cancer
November 23rd 2020In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.
Read More
Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis
November 19th 2020In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.
Read More
Raez Raises Concerns Over Delayed Cancer Care in the COVID-19 Era
November 16th 2020In our exclusive interview, Dr. Raez discusses the reasons for the declines in routine screening and referrals due to the coronavirus disease 2019, anticipated consequences, and some of the ways in which the health care community can combat these newfound challenges.
Read More
Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer
November 12th 2020In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.
Read More
Aggarwal and Gandara on Incorporating Liquid Biopsies Into the Lung Cancer Armamentarium
November 9th 2020In our exclusive interview, Dr. Aggarwal and Dr. Gandara discuss the evolution of liquid biopsy in lung cancer, explain the clinical implications of recent liquid biopsy approvals, and forecast the future of liquid biopsy in the field.
Read More
Tripathy Talks Genomics, Targeted Treatments, and Smart Trial Designs in Breast Cancer
November 6th 2020In our exclusive interview, Debu Tripathy, MD, considers the biological and long-term outcome variability of HR-positive, HER2-negative breast cancer and details the research that is being done to develop personalized treatment approaches.
Read More
Lyman on Bringing Biosimilars From Bench to Bedside in Oncology
November 2nd 2020In our exclusive interview, Gary H. Lyman, MD, MPH, discusses the current state of biosimilars in oncology, the pathways that have been established to ensure the safe delivery of these agents to patients, and the potential effects they could have on alleviating some of the current constraints within the health care system.
Read More
Raez on the Rise of Liquid Biopsy in Lung Cancer
October 29th 2020In our exclusive interview, Dr. Raez provides insight into the advantages and disadvantages of liquid biopsy relative to tissue biopsy and forecasts the utility of liquid biopsy within the field of lung cancer as more of these assays become available.
Read More
Gandara Evaluates Opportunities for Virtual Education, Expansion, and Engagement Amid COVID-19
October 19th 2020In our exclusive interview, David R. Gandara, MD highlights the benefits and challenges of delivering patient care virtually and its reception among patients, discusses the sustainability of virtual CME platforms and forecasts what the “new normal” of oncology education may look like as a result of the pandemic.
Read More
Garcia-Manero Previews Potential Therapeutic Standards in TP53-Mutated MDS/AML
October 15th 2020In our exclusive interview, Guillermo Garcia-Manero, MD, discusses the prevalence of TP53 mutations in myelodysplastic syndromes and acute myeloid leukemia, the prognosis these mutations confer, and the development of eprenetapopt and magrolimab in this patient population.
Read More
Gutierrez Provides Insight on Bridging Gaps in Cancer Care
October 12th 2020In our exclusive interview, Rodolfo Gutierrez, MD, discusses the issues that surround access to care and clinical outcomes with Hispanic patients, efforts The Angeles Clinic has spearheaded to bridge this gap in care, and the importance of patient and provider education and awareness.
Read More
Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors
October 8th 2020In our exclusive interview, Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in tumor mutational burden–high solid tumors, shares the “transformative importance” of the regulatory decision, and speaks to the controversy surrounding the approval.
Read More
O’Regan on Protocols, Best Practices, and Virtual Etiquette for Cancer Care in Light of COVID-19
October 5th 2020In our exclusive interview, O’Regan discusses the protocols the University of Wisconsin Carbone Cancer Center has put into place in light of COVID-19, the rise of telemedicine, best practices for in-person visits in the clinic, and the importance of maintaining well visits throughout the pandemic.
Read More
FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
October 1st 2020In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.
Read More
FDA Approval Insights: Fixed-Dose Pertuzumab/Trastuzumab in HER2+ Breast Cancer
September 28th 2020In our exclusive interview, Antoinette R. Tan, MD, of Atrium Health, discusses the FDA approval of the fixed-dose combination of pertuzumab and trastuzumab in HER2-positive breast cancer and highlights the results of the pivotal FeDeriCa trial.
Read More
FDA Approval Insights: Lurbinectedin in Metastatic SCLC
September 24th 2020In our exclusive interview, Jacob Sands, MD, discusses the FDA approval of lurbinectedin in small cell lung cancer and shed light on key findings from the phase 2 basket trial that served as the basis for the approval.
Read More
Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer
September 21st 2020In our exclusive interview, Dr. Tripathy discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.
Read More
FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma
September 17th 2020In our exclusive interview, Omid Hamid, MD, contextualizes the FDA approval of atezolizumab in combination with cobimetinib and vemurafenib in BRAF V600 mutation–positive advanced melanoma and discusses important takeaways from the IMspire150 trial.
Read More
Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer
September 14th 2020In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.
Read More
Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer
September 10th 2020In our exclusive interview, Sara M. Tolaney, MD, MPH, shares insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.
Read More
Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
September 7th 2020In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.
Read More
Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer
September 3rd 2020In our exclusive interview, Robert L. Coleman, MD, FACOG, FACS and Brian M. Slomovitz, MD, discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.
Read More
GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer
August 31st 2020Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.
Read More